XML 65 R47.htm IDEA: XBRL DOCUMENT v3.20.1
Collaborative Agreements (Details)
 1 Months Ended 3 Months Ended 12 Months Ended
Apr. 11, 2018
USD ($)
Dec. 29, 2017
Aug. 07, 2015
product
Mar. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Sep. 30, 2015
USD ($)
Dec. 31, 2019
USD ($)
Sep. 30, 2019
USD ($)
Jun. 30, 2019
USD ($)
Mar. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Sep. 30, 2018
USD ($)
Jun. 30, 2018
USD ($)
Mar. 31, 2018
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Revenues             $ 279,488 $ 866,863 $ 135,673 $ 2,829,905 $ 2,502,624 $ 2,000,868 $ 24,448,761 $ 1,529,644 $ 4,111,930 $ 30,481,897 $ 42,220,086
Deferred grant funding             6,065,212       4,165,848       6,065,212 4,165,848  
ApolloBio | Collaborative Arrangement                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Territory expansion option period   3 years                              
Proceeds from collaborative agreement       $ 19,400,000                          
Upfront payment received       23,000,000                     23,000,000    
Advisory fees       960,000                   $ 960,000      
Additional revenue to be achieved                             $ 20,000,000    
Obligation period to pay royalties                             10 years    
Agreement period from effective date for termination                             1 year    
Agreement, number of days written notice before termination                             90 days    
AstraZeneca                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Revenues                             $ 3,200,000    
AstraZeneca | Collaborative Arrangement                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Upfront payment received           $ 27,500,000                     $ 27,500,000
Agreement anticipated development and regulatory event based payment receivable milestones                             125,000,000    
Agreement, anticipated commercial event based payment receivable milestones                             115,000,000    
Number of additional products | product     2                            
Agreement, milestone payment, revenue recognized         $ 2,000,000                        
Accounts receivable             200,000       $ 3,200,000       200,000 3,200,000  
Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Upfront payment received                             6,300,000 $ 4,300,000  
Collaborative agreement, funding to be received $ 56,000,000                                
Collaborative agreement, period to receive funding for research and development 5 years                                
Deferred grant funding             $ 5,000,000               $ 5,000,000    
Foreign Tax Authority | ApolloBio | Collaborative Arrangement                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Collaborative agreement, corporate income tax       2,200,000                          
Collaborative agreement, foreign non-income Taxes       $ 1,400,000